Serum vitamin D deficiency and risk of hospitalization for heart failure: Prospective results from the Moli-sani study

Pounis, George; Donati, M.B.; Iacoviello, Licia; Donati, Maria Benedetta; Gaetano, Giovanni de; Vermylen, Jos; Carrasco, Ignacio De Paula; Giampaoli, Simona; Spagnuolo, Antonio; Assanelli, Deodato; Centritto, Vincenzo; Spagnuolo, Pasquale; Staniscia, Dante; Zito, Francesco; Bonanni, Americo; Cerletti, Chiara; Curtis, Amalia De; Castelnuovo, Augusto Di; Lorenzet, Roberto; Mascioli, A.; Olivieri, Marco; Rotilio, Domenico; Bonaccio, Marialaura; Costanzo, Simona; Gianfagna, Francesco; Giacci, Maurizio; Padulo, Antonella; Petraroia, Dario; Grippi, Claudio; Magnacca, Sara; Marracino, Federico; Spinelli, Maria; Silvestri, Christian; Lucia, Francesca De; Izzi, Benedetta; Vohnout, Branislav; Zito, Franco; Persichillo, Mariarosaria; Verna, Angelita; Lillo, Maura Di; Stefano, Irene Di; Pampuch, Agnieszka; Pannichella, Agostino; Vizzarri, Antonio Rinaldo; Arcari, Antonella; Barbato, Daniela; Bracone, Francesca; Giorgio, Carmine; Panebianco, Simona; Chiovitti, Antonello; Caccamo, Sergio; Caruso, Vanesa; Rago, Livia; Cugino, Daniela; Ferri, Alessandra; Castaldi, Concetta; Mignogna, Marcella; Guszcz, Tomasz; Giuseppe, Romina di; Barisciano, Paola; Buonaccorsi, Lorena; Centritto, Floriana; Cutrone, Antonella; Fanelli, Francesca; Santimone, Iolanda; Sciarretta, Anna; Sorella, Isabella; Plescia, Emanuela; Molinaro, Alessandra; Cavone, C.; Galuppo, Giovanna; D'Angelo, Dolores; Ramacciato, Rosanna

doi:10.1016/j.numecd.2017.11.008

Cited by 27 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar data came from a study on 274 elderly (mean age 69 years) postmenopausal women living in Warsaw [28] [30][31][32]. Zhang et al [33]. reported a plateau above 20 ng/mL for incidence, but much higher for mortality.…”

Section: Discussionsupporting

confidence: 59%

Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study

et al. 2021

View full text Add to dashboard Cite

Background: Anemia and vitamin D deficiency are common factors in chronic heart failure (CHF). The aim of this study was to assess vitamin D levels as well as its binding protein and anemia in relation to a cause of CHF: coronary heart disease, valvular disease and cardiomyopathy. Methods: One hundred and sixteen consecutive patients (36 females and 80 males) with CHF were admitted for percutaneous coronary interventions (PCI). Hemoglobin concentration, serum creatinine, B-type natriuretic peptide (BNP), 25-hydroxyvitamin D [25(OH)D] and its binding protein-VDBP were measured. Results: The prevalence of anemia was 22%. BNP was the highest in the group with coronary artery disease. Ejection fraction was the lowest in cardiomyopathy group. 25(OH)D was lowest in valvular disease group, significantly lower than in the coronary artery group. A similar pattern of change showed vitamin D binding protein. The prevalence of vitamin D deficiency (level below 20 ng/mL) in the whole group was 95%, in 49% of the patients 25(OH)D was below 10 ng/mL. In univariate analysis 25(OH)D correlated with hemoglobin, red blood cell count, hematocrit, mean corpuscular volume and BNP in patients with CHF in the whole group. In multiple regression analysis, predictors of 25(OH)D were estimated, glomerular filtration rate, BNP and valvular disease. Conclusions: 25(OH)D deficiency is common in CHF patients. Valvular disease is associated the most severe vitamin D deficiency and worsened kidney function. A higher prevalence of anemia in CHF due to coronary heart disease may be associated with wider use of angiotensin converting enzyme inhibitors and acetylsalicylic acid. Heart and kidney function are predictors of 25(OH)D level in the patients of this study.

show abstract

Section: Discussionsupporting

confidence: 59%

Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…58 In an Italian prospective study of 19 092 men, vitamin D levels and HAHF were analysed. 58 In an Italian prospective study of 19 092 men, vitamin D levels and HAHF were analysed.…”

Section: Myocardial Remodellingmentioning

confidence: 99%

“…Mainly as a result of obesity, vitamin D levels are lower in people with type 2 diabetes, and vitamin D deficiency has been shown to increase the rate of HAHF. 58 In an Italian prospective study of 19 092 men, vitamin D levels and HAHF were analysed. Those who were deficient (levels <10 ng/mL) had a significant 61% increase in HF compared with those who were vitamin D-sufficient (levels >30 ng/mL).…”

Section: Myocardial Remodellingmentioning

confidence: 99%

Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications

Bell¹,

Goncalves

2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

In people with type 2 diabetes the frequency of heart failure (HF) is increased and mortality from HF is higher than with non-diabetic HF. The increased frequency of HF is attributable to the cardiotoxic tetrad of ischaemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the renin-angiotensin-aldosterone system and sympathetic nervous systems results in cardiac remodelling, which worsens cardiac function. Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin-converting enzyme inhibitors and β-blockers. However, with HF with preserved ejection fraction (HFpEF), only therapy for the underlying risk factors helps.Blockers of mineralocorticoid receptors may be beneficial in both HFrEF and HFpEF. Glucoselowering drugs can have a negative effect (insulin, sulphonylureas, dipeptidyl peptidase-4 inhibitors and thiazolidinediones), a neutral effect (α-glucosidase inhibitors and glucagon-like peptide-1 receptor agonists) or a positive effect (sodium-glucose co-transporter-2 inhibitors and metformin).antidiabetic drug, GLP-1 analogue, heart failure, insulin therapy, SGLT2 inhibitor, thiazolidinediones 1 | INTRODUCTION Heart failure (HF) results from structural and/or functional impairment of ventricular filling and/or ejection 1 and it is a common and serious comorbidity of type 2 diabetes. 2 In the present review we document the increased incidence of HF, and the reasons for this increase, as well as its poor prognosis in patients with diabetes.The potential therapies to both prevent and treat HF are discussed, in addition to the positive and negative effects of glucoselowering medications.Several reviews on this important subject have been recently published 3-7 ; however, this is a rapidly evolving field. An important limitation has been that HF was not a primary endpoint in most cardiovascular (CV) outcome trials, and it has been the most heterogeneously distributed outcome. | EPIDEMIOLOGYAs long ago as the Framingham Heart Study, HF was shown to be twice as common in men with diabetes and five times more common in women with diabetes between the ages of 45 and 74 years when compared with age-matched non-diabetic controls, and, in those aged ≤65 years, there was a fourfold increase in the prevalence of HF in men with diabetes and an eightfold increase in women with diabetes. 8In almost 10 000 patients with type 2 diabetes enrolled in a Health Maintenance Organization, 12% had HF at entry. Independent risk factors for the presence of HF were older age, longer duration of diabetes, use of insulin and lower body mass index (BMI). 9 In addition, those with type 2 diabetes who did not have HF at entry developed HF at a rate of 3.3% per year. The Reykjavik Study reported a 12% prevalence of HF in people with diabetes compared with 3% in people

show abstract

“…They concluded that low vitamin D levels were independently associated with a higher risk of readmission and driveline infection risk [ 38 ]. Similarly, a cohort study investigated the relationship between serum vitamin D and the incidence of hospitalization in heart failure patients [ 39 ]. A greater risk of hospitalization was observed in deficient patients with a hazard ratio of 1.61 when compared to those with normal levels [ 39 ].…”

Section: Reviewmentioning

confidence: 99%

Role of Vitamin D Supplementation in Heart Failure Patients With Vitamin D Deficiency and Its Effects on Clinical Outcomes: A Literature Review

Busa

Dardeir

Marudhai

et al. 2020

Cureus

View full text Add to dashboard Cite

Vitamin D deficiency has become a global pandemic affecting approximately one billion people worldwide. Much attention has been paid to the association of low serum 25-hydroxyvitamin D (25(OH)D) levels and various chronic diseases, especially heart failure (HF). A clear role of vitamin D deficiency has been established, with increased mortality and morbidity in heart failures. However, previous randomized control trials have failed to show improvement in clinical outcomes with calciferol supplementation in these patients. Therefore, it is still unclear whether calciferol therapy can be added to the standard care in congestive heart failure (CHF) patients with deficiency. Hence, to evaluate the role of vitamin D supplementation in CHF patients with low serum 25(OH)D, we conducted an extensive search in the PubMed and Google Scholar databases using various combinations of keywords. All potentially eligible studies that evaluated the effects of vitamin D supplementation on clinical outcomes in HF patients were retrieved and extensively studied. We also checked the references of all eligible studies to identify additional relevant publications. In this study, we reviewed various mechanisms of vitamin D affecting the cardiovascular system and examined the impact of deficiency on heart failures in terms of mortality and hospitalizations. In conclusion, vitamin D supplementation has failed to improve the clinical outcomes in HF patients. The possible long-term benefits of supplementation cannot be excluded. Therefore, for future clinical trials, we recommend considering large sample sizes, longer follow-up durations, along with optimal dosage and appropriate dosing frequency.

show abstract

Serum vitamin D deficiency and risk of hospitalization for heart failure: Prospective results from the Moli-sani study

Cited by 27 publications

References 29 publications

Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study

Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study

Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications

Role of Vitamin D Supplementation in Heart Failure Patients With Vitamin D Deficiency and Its Effects on Clinical Outcomes: A Literature Review

Contact Info

Product

Resources

About